BPG is committed to discovery and dissemination of knowledge
Articles in Press
6/25/2026 2:58:48 AM | Browse: 2 | Download: 0
Publication Name World Journal of Clinical Oncology
Manuscript ID 121993
Country China
Category Oncology
Manuscript Type Minireviews
Article Title Harnessing minimal residual disease for precision medicine in locally advanced gastric cancer
Manuscript Source Invited Manuscript
All Author List Xiao-Wei Guo, Xin-Xin Xu, Bing-Jie Deng, Guang-Fu Zhou, Qian Zhou, Xiao-Xin Gao, Cheng-Zhou Du, Zhi Qiao and Hong-Tao Li
Funding Agency and Grant Number
Funding Agency Grant Number
Military Health Care Project 24BJZ15
Gansu Provincial Science and Technology Project 25JRRA1191
Corresponding Author Hong-Tao Li, Associate Chief Physician, Associate Professor, Department of General Surgery, The 940th Hospital of Joint Logistics Support Force of Chinese People’s Liberation Army, No. 333 South River Road, Lanzhou 730050, Gansu Province, China. lihongtao528@163.com
Key Words Locally advanced gastric cancer; Minimal residual disease; Circulating tumor DNA; Recurrence prediction; Treatment guidance; Neoadjuvant therapy
Core Tip Locally advanced gastric cancer remains difficult to cure because occult residual disease can drive recurrence after radical or multimodal therapy. Minimal residual disease (MRD) assessment using circulating tumor DNA (ctDNA) offers a non-invasive strategy for molecular surveillance, recurrence-risk stratification, and dynamic evaluation of treatment response. This minireview highlights current ctDNA-MRD technologies, introduces tumor-informed and tumor-agnostic approaches, and clarifies that ctDNA-MRD is promising but still investigational for treatment guidance. Standardized assays, validated thresholds, and prospective interventional trials are needed before routine precision management of locally advanced gastric cancer.
Citation Guo XW, Xu XX, Deng BJ, Zhou GF, Zhou Q, Gao XX, Du CZ, Qiao Z, Li HT. Harnessing minimal residual disease for precision medicine in locally advanced gastric cancer. World J ClinOncol 2026; In press
Received
2026-04-08 03:35
Peer-Review Started
2026-04-08 03:37
First Decision by Editorial Office Director
2026-05-27 08:13
Return for Revision
2026-05-27 09:11
Revised
2026-06-10 08:39
Publication Fee Transferred
Second Decision by Editor
2026-06-25 02:30
Second Decision by Editor-in-Chief
Final Decision by Editorial Office Director
2026-06-25 02:58
Articles in Press
2026-06-25 02:58
Edit the Manuscript by Language Editor
Typeset the Manuscript
ISSN 2218-4333 (online)
Open Access This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright © The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com